Tag:
Joe Jimenez
Latest Headlines
Latest Headlines
Where should pharma go? Depends which CEO you ask
Three continents, three drugmakers, three lenses for viewing pharma's future. Which gives the clearest glimpse of Pharma Next? You decide.
Novartis CEO Jimenez focuses R&D on the new blockbuster paradigm
For many pharma companies like, say, Eli Lilly, the focus in R&D has been taking the big bats and swinging for the proverbial fences, looking for breakthrough drugs that can instantly command billions in annual revenue. That strategy has been on display for Alzheimer's as well as heart drugs, where Lilly has been pursuing questionable scientific strategies in search of the golden blockbuster ticket.
Novartis welcomes ex-COO as chairman
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Novartis' Jimenez says no need to sell Roche stake
With a new chairman selected to take the helm of Novartis, lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.
Novartis braces for $3.5B hit to 2013 sales
Flat sales and lower profits. These aren't predictions that shareholders like to hear. But like other Big Pharmas before it, Novartis faces generic competition for its biggest drugs. And like its rivals, the Swiss drugmaker is bracing for continued fallout.
Novartis nabs EU approval for meningitis B vaccine Bexsero
Novartis has won European approval of Bexsero, its new meningitis B vaccine, which is central to the Big Pharma's drive to grow its big vaccine unit.
Novartis CEO pay cited as Swiss weigh limits to exec compensation
The Swiss are up in arms over executive pay again and, once again, Novartis ($NVS) executives are key exhibits in their case.
Novartis CEO pay cited as Swiss weigh limits to exec compensation
The Swiss are up in arms over executive pay again, and once again, Novartis ($NVS) executives are key exhibits in their case. This time, a fair-pay initiative will go up for nationwide vote, giving citizens the chance to weigh in on executive compensation.
Novartis CEO shopping for bolt-on deals at $4B, tops
Yesterday, analysts predicted that 2013 would be the year Big Pharma would take bigger bites from the M&A apple. But don't count Novartis ($NVS) among the crowd willing to pay $10 billion or more for the right company. CEO Joe Jimenez says his appetite is limited to $4 billion at most.
Novartis grabs EU committee support for first meningitis B vaccine
Novartis has scored a key endorsement for one of the brightest stars from its vaccines division. The European Union's Committee for Medicinal Products for Human Use (CHMP) backed approval of Bexsero, the Swiss drug giant's ($NVS) meningitis B vaccine that could become the first such shot to hit the market if the European Commission follows the CHMP's advice.
